Research work · 2015

Advances in Anticancer Immunotoxin Therapy

Christine Alewine, Raffit Hassan, Ira H Pastan

The Oncologist

Abstract

Immunotoxins are a novel class of antibody-conjugated therapeutics currently in clinical development for a variety of malignancies. They consist of an antibody-based targeting domain fused to a bacterial toxin payload for cell killing. Immunotoxins kill cells by inhibiting protein synthesis, a unique mechanism of action that is toxic to both dividing and nondividing cells. Recent advances in the design and administration of immunotoxins are overcoming historical challenges in the field, leading to renewed interest in these therapeutics.

Download PDF

DOI: 10.1634/theoncologist.2014-0358